Domestic Pharma BD Deal: Qilu Pharmaceutical Inks Agreement with Biomaterials Innovator Baimai Biopharma for Mid-to-Late-Stage Hepatocellular Carcinoma Therapy BM601

Sep 17, 2025 09:50 CST Updated 09:51

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators Summit Scan to register

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprint requires authorization.

PharmaCircleLearned: Recently, BioMab (Suzhou) Biopharmaceutical Co., Ltd. ("BioMab") from Suzhou, Jiangsu, and Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") have officially reached a project cooperation agreement on BioMab's self-developed metal embolic microsphere BM601 product for TACE treatment of liver cancer.

According to the terms of this BD&L agreement, Biomay Biotechnology will receiveTotal amount exceeds 200 million RMBMilestone payments, additional sales royalties, and overseas revenue sharing.

The cooperative project BM601 this time is a Class III medical device product independently developed by BioMind based on the original technology of Professor Liu Zhuang's team from Soochow University. It has independent intellectual property rights, and its unique mechanism of action can significantly enhance the therapeutic effect of transarterial chemoembolization (TACE). In early clinical studies targeting patients with unresectable primary liver cancer, it demonstrated significant clinical advantages and is expected to bring more effective treatment options for patients with intermediate to advanced liver cancer. The clinical trial was conducted byZhongda Hospital Affiliated to Southeast UniversityAcademician Teng GaojunLed by, the previously expected listing time frame was in2027。

It is worth mentioning that this time isThe second deal reached by Baimai Biotech. The previous deal was with Faber Xin Tian, a pharmaceutical company in the field of nuclear medicine.

Baimai Biotech has laid out new delivery and controlled-release technologies to achieve precise regulation of the immune microenvironment; aiming to

Pioneering a New Generation of Treatment Solutions for Tumors and Inflammatory Diseases;The founder is Professor Liu Zhuang.BM201, developed by Baimai Biotech, is a TLR7/8 agonist.Micronized sustained-release formulation.

Moxie Pharma Data pharma.bcpmdata.com (formerly known as Yaoke Rongyun Data)

References:

Moxie Pharma Data pharma.bcpmdata.com (formerly Pharma Intelligence Cloud Data);

http://innobm.com/；

https://www.qilu-pharma.com/；

http://innobm.com/info-76-143.html；

Liu Zhuang: A New Approach to Treating Tumors,

https://mp.weixin.qq.com/s/sucjtncBTgOwwvPyjL2Slg；

clinicaltrials@innobm.com; etc.

After remarks, you can scan the code to join the PharmaCircle communication group.

The following conferences are featured in the header image; you can scan the banner in the header image to register.

Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceutical industry. With the mission of "enabling the boundless flow of intelligence and connections," it has established an empowerment system that covers the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, an industry think tank, and ecosystem communities—it builds the infrastructure for the flow of pharmaceutical value in China.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources—serving not only as a hub for information and networking but also as a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.

Like

Share

Point Recommendation